EAGLE-eyed reanalysis clarifies cognitive benefits of BioLineRx's schizophrenia contender
This article was originally published in Scrip
An unnamed third party reviewed Phase IIb clinical trial results for the schizophrenia drug candidate BL-1020 and found that the BioLineRx antipsychotic significantly improved cognitive impairment more than the Israeli company revealed in its own analysis first published in 2009.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.